178 related articles for article (PubMed ID: 35165767)
1. Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
Buonomo AR; Viceconte G; Calabrese M; De Luca G; Tomassini V; Cavalla P; Maniscalco GT; Ferraro D; Nociti V; Radaelli M; Buscarinu MC; Paolicelli D; Gajofatto A; Annovazzi P; Pinardi F; Di Filippo M; Cordioli C; Zappulo E; Scotto R; Gentile I; Spiezia AL; Petruzzo M; De Angelis M; Brescia Morra V; Solaro C; Gasperini C; Cocco E; Moccia M; Lanzillo R;
J Neurol; 2022 Jun; 269(6):3301-3307. PubMed ID: 35165767
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B reactivation is a rare event among patients with resolved infection undergoing anti-CD20 antibodies in monotherapy without antiviral prophylaxis: results from the HEBEM study.
Marzo B; Vidal-Jordana A; Castilló J; Robles-Sanchez MA; Otero-Romero S; Tintore M; Montalban X; Buti M; Riveiro-Barciela M
J Neurol; 2024 Jan; 271(1):134-140. PubMed ID: 37695530
[TBL] [Abstract][Full Text] [Related]
3. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
[TBL] [Abstract][Full Text] [Related]
4. Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey.
Çelik M; Baba C; Irmak Ç; Özakbaş S; Avkan-Oğuz V
J Neurol; 2024 Apr; ():. PubMed ID: 38578494
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab.
Zappulo E; Nicolini LA; Di Grazia C; Dominietto A; Lamparelli T; Gualandi F; Caligiuri P; Bruzzone B; Angelucci E; Viscoli C; Mikulska M
Infection; 2019 Feb; 47(1):59-65. PubMed ID: 30232604
[TBL] [Abstract][Full Text] [Related]
6. Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma.
Guarino M; Picardi M; Vitello A; Pugliese N; Rea M; Cossiga V; Pane F; Caporaso N; Morisco F
Ann Hepatol; 2017; 16(2):198-206. PubMed ID: 28233742
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus among hematopoietic stem cell transplant recipients: Antiviral impact in seroconversion, engraftment, and mortality in a Latin American center.
Buzo BF; Ramos JF; Marques Rossetti RA; Salles N; Mendrone-Júnior A; Rocha V; de Seixas Santos Nastri AC
Transpl Infect Dis; 2020 Apr; 22(2):e13243. PubMed ID: 31901206
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection.
Megna M; Patruno C; Bongiorno MR; Gambardella A; Guarneri C; Romita P; Raimondo A; Loconsole F; Fabbrocini G
Clin Drug Investig; 2022 Jun; 42(6):525-531. PubMed ID: 35633470
[TBL] [Abstract][Full Text] [Related]
10. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.
Yang HC; Tsou HH; Pei SN; Chang CS; Chen JH; Yao M; Lin SJ; Lin J; Yuan Q; Xia N; Liu TW; Chen PJ; Cheng AL; Hsu C;
J Hepatol; 2018 Aug; 69(2):286-292. PubMed ID: 29551710
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
[TBL] [Abstract][Full Text] [Related]
12. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy.
Fidan S; Capkın E; Arıca DA; Durak S; Okatan IE
Int J Rheum Dis; 2021 Feb; 24(2):254-259. PubMed ID: 33244900
[TBL] [Abstract][Full Text] [Related]
13. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
[TBL] [Abstract][Full Text] [Related]
14. Prevention of hepatitis B virus reactivation in patients with hematological malignancies and resolved hepatitis B virus infection: a systematic review and meta-analysis.
Cheung CKM; Law MF; Chao DC; Wong SH; Ho R; Chao ACW; Lai JWY; Chan TYT; Tam MTK; Lau SLF; Tam THC
J Dig Dis; 2020 Mar; 21(3):160-169. PubMed ID: 32040243
[TBL] [Abstract][Full Text] [Related]
15. Patients treated with rituximab are poorly screened for hepatitis B infection: Data from a low-incidence country.
Brakenhoff SM; Hoekstra R; Honkoop P; Roomer R; den Hollander JG; Bezemer G; de Knegt RJ; Sonneveld MJ; de Man RA
Eur J Intern Med; 2023 Feb; 108():68-73. PubMed ID: 36462966
[TBL] [Abstract][Full Text] [Related]
16. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper.
Sarmati L; Andreoni M; Antonelli G; Arcese W; Bruno R; Coppola N; Gaeta GB; Galli M; Girmenia C; Mikulska M; Pane F; Perno CF; Picardi M; Puoti M; Rambaldi A; Svicher V; Taliani G; Gentile G
Clin Microbiol Infect; 2017 Dec; 23(12):935-940. PubMed ID: 28668466
[TBL] [Abstract][Full Text] [Related]
17. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
Varisco V; Viganò M; Batticciotto A; Lampertico P; Marchesoni A; Gibertini P; Pellerito R; Rovera G; Caporali R; Todoerti M; Covelli M; Notarnicola A; Atzeni F; Sarzi-Puttini P
J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
[TBL] [Abstract][Full Text] [Related]
18. Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection.
Sayar S; Kürbüz K; Kahraman R; Öztürk O; Çalışkan Z; Doğanay HL; Özdil K
Turk J Gastroenterol; 2020 Jul; 31(7):522-528. PubMed ID: 32897226
[TBL] [Abstract][Full Text] [Related]
19. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
20. [Latest Treatment of Viral Hepatitis--Overcoming Hepatitis C and Reactivation of Hepatitis B].
Tanaka Y
Rinsho Byori; 2016 Feb; 64(2):211-8. PubMed ID: 27311286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]